Lack of IFN-γ production in response to antigenic stimulation in human IFN-τ-treated lymphocytes

Journal of Interferon and Cytokine Research

Volumn 25, Issue 8, 2005, Pages 444-452

  Rogez Kreuz, Christine ^a,b   Manéglier, Benjamin ^c   Dereuddre Bosquet, Nathalie ^a   Dormont, Dominique ^a   Clayette, Pascal ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b INRA Institut National de la Recherche Agronomique   (France)

^c CENTRE HOSPITALIER DE VERSAILLES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON; LIPOPOLYSACCHARIDE; TAU INTERFERON; TUBERCULIN;

ANIMAL CELL; ARTICLE; AUTOIMMUNE DISEASE; BOVIDS; CONTROLLED STUDY; ENCEPHALITIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOSTIMULATION; INTERFERON PRODUCTION; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PURIFICATION; TH1 CELL; VIRUS INHIBITION; VIRUS REPLICATION;

MURINAE; OVIS;

EID: 23944444343     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2005.25.444     Document Type: Article

References (55)

1. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu. Rev. Biochem. 1998; 67:227-264.
2. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 1996;17:369-372.
3. Parronchi P, De Carli M, Manetti R, Simonelli C, Sampognaro S, Piccinni MP, Macchia D, Maggi E, Del Prete G, Romagnani S. IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones. J. Immunol. 1992;149:2977-2983.
4. Parronchi P, Mohapatra S, Sampognaro S, Giannarini L, Wahn U, Chong P, Mohapatra S, Maggi E, Renz H, Romagnani S. Effects of interferon-alpha on cytokine profile, T cell receptor repertoire and peptide reactivity of human allergen-specific T cells. Eur. J. Immunol. 1996;26:697-703.
5. Hunter CA, Gabriel KE, Radzanowski T, Neyer LE, Remington JS. Type I interferons enhance production of IFN-gamma by NK cells. Immunol. Lett. 1997;59:1-5.
6. Biron CA. Activation and function of natural killer cell responses during viral infections. Curr. Opin. Immunol. 1997;9:24-34.
7. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 2002;14: 432-436.
8. Santini SM, Di Pucchio T, Lapenta C, Parlato S, Logozzi M, Belardelli F. The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity. J. Interferon Cytokine Res. 2002;22:1071-1080.
9. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J. Exp. Med. 2000;192:219-226.
10. + T cells. J. Exp. Med. 1993;178:1655-1663.
11. Rogge L, D'Ambrosio D, Biffi M, Penna G, Minetti LJ, Presky DH, Adorini L, Sinigaglia F. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J. Immunol. 1998;161:6567-6574.
12. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996;383:787-793.
13. Romagnani S. Understanding the role of Th1/Th2 cells in infection. Trends Microbiol. 1996;4:470-473.
14. Cacoub P, Benhamou Y. [Role of interferons in the treatment of hepatitis B and hepatitis C virus infections.] Rev. Med. Interne 2002;23(Suppl 4):459s-474s.
15. Krown SE. IFN-α: evolving therapy for AIDS-associated Kaposi's sarcoma. J. Interferon Cytokine Res. 1998;18:209-214.
16. Coyle PK, Hartung HP. Use of interferon beta in multiple sclerosis: rationale for early treatment and evidence for dose- and frequency-dependent effects on clinical response. Mult. Scler. 2002;8:2-9.
17. Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, Zhang JZ. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999;53:1692-1697.
18. Rep MH, Schrijver HM, van Lopik T, Hintzen RQ, Roos MT, Ader HJ, Polman CH, van Lier RA. Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients. J. Neuroimmunol. 1999;96:92-100.
19. Huang YM, Stoyanova N, Jin YP, Teleshova N, Hussien Y, Xiao B, Fredrikson S, Link H. Altered phenotype and function of blood dendritic cells in multiple sclerosis are modulated by IFN-beta and IL-10. Clin. Exp. Immunol. 2001;124:306-314.
20. Furlan R, Bergami A, Lang R, Brambilla E, Franciotta D, Martinelli V, Comi G, Panina P, Martino G. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J. Neuroimmunol. 2000;111:86-92.
21. Xing T, Zhang L, Lu Q, Hou J, Feng X, Luo K. Th1/Th2 type cytokines in hepatitis B patients treated with interferon-alpha. Chin. Med J. (Engl.) 2001;114:921-924.
22. Shinohara M, Ishii K, Takamura N. Long-term changes of peripheral blood CD4-positive T cell subsets (Th1, Th2) in chronic hepatitis C patients with a sustained response or no response to IFN. Hepatol. Res. 2003;27:260-265.
23. Amati L, Caradonna L, Magrone T, Mastronardi ML, Cuppone R, Cozzolongo R, Manghisi OG, Caccavo D, Amoroso A, Jirillo E. Modifications of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-alpha/ribavirin. Curr. Pharm. Des. 2002;8:981-993.
24. Cacciarelli TV, Martinez OM, Gish RG, Villanueva JC, Krams SM. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996;24: 6-9.
25. Clerici M, Shearer GM. A Th1 → Th2 switch is a critical step in the etiology of HIV infection. Immunol. Today 1993;14;107-111.
26. Romagnani S, Maggi E. Th1 versus Th2 responses in AIDS. Curr. Opin. Immunol. 1994;6:616-622.
27. Vieillard V, Cremer I, Lauret E, Rozenbaum W, Debre P, Autran B, De Maeyer E. Interferon beta transduction of peripheral blood lymphocytes from HIV-infected donors increases Th1-type cytokine production and improves the proliferative response to recall antigens. Proc. Natl. Acad. Sci. USA 1997;94:11595-11600.
28. Liu L, Leaman DW, Bixby JA, Roberts RM. A type I ovine interferon with limited similarity to IFN-alpha, IFN-omega and IFN-tau: gene structure, biological properties and unusual species specificity. Biochim. Biophys. Acta 1996;1294:55-62.
29. Martal JL, Chene NM, Huynh LP, L'Haridon RM, Reinaud PB, Guillomot MW, Charlier MA, Charpigny SY. IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie 1998;80:755-777.
30. Roberts RM. IFN-τ and pregnancy. J. Interferon Cytokine Res. 1996;16:271-273.
31. Pontzer CH, Bazer FW, Johnson HM. Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1. Cancer Res. 1991;51:5304-5307.
32. Rogez C, Martin M, Dereuddre-Bosquet N, Martal J, Dormont D, Clayette P. Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and beta-chemokines. J. Virol. 2003;77:12914-12920.
33. Pontzer CH, Torres BA, Vallet JL, Bazer FW, Johnson HM. Antiviral activity of the pregnancy recognition hormone ovine trophoblast protein-1. Biochem. Biophys. Res. Commun. 1988;152:801-807.
34. Soos JM, Subramaniam PS, Hobeika AC, Schiffenbauer J, Johnson HM. The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J. Immunol. 1995;155:2747-2753.
35. Dereuddre-Bosquet N, Clayette P, Martin M, Mabondzo A, Fretier P, Gras G, Martal J, Dormont D. Anti-HIV potential of a new interferon, interferon-tau (trophoblastin). J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996;11:241-246.
36. Subramaniam PS, Khan SA, Pontzer CH, Johnson HM. Differential recognition of the type I interferon receptor by interferons tau and alpha is responsible for their disparate cytotoxicities. Proc. Natl. Acad. Sci. USA 1995;92:12270-12274.
37. Mujtaba MG, Streit WJ, Johnson HM. IFN-tau suppresses both the autoreactive humoral and cellular immune responses and induces stable remission in mice with chronic experimental allergic encephalomyelitis. Cell. Immunol. 1998;186:94-102.
38. Chaouat G, Assal Meliani A, Martal J, Raghupathy R, Elliot J, Mosmann T, Wegmann TG. IL-10 prevents naturally occurring fetal loss in the CBA X DBA/2 mating combination, and local defect in IL-10 production in this abortion-prone combination is corrected by in vivo injection of IFN-tau. J. Immunol. 1995;154:4261-4268.
39. Mujtaba MG, Soos JM, Johnson HM. CD4 T suppressor cells mediate interferon tau protection against experimental allergic encephalomyelitis. J. Neuroimmunol. 1997;75:35-42.
40. Soos JM, Stuve O, Youssef S, Bravo M, Johnson HM, Weiner HL, Zamvil SS. Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate. J. Immunol. 2002;169:2231-2235.
41. Henderson DC, Rippin JJ. Stimulus-dependent production of cytokines and pterins by peripheral blood mononuclear cells. Immunol. Lett. 1995;45:29-34.
42. Skoberne M, Malovrh T, Skralovnik-Stern A, Kotnik V. Human peripheral blood lymphocytes sensitised to PPD respond to in vitro stimulation with increased expression of CD69 and CD134 activation antigens and production of Th1- type cytokines. Pflugers Arch. 2000;440(Suppl. 5):R58-60.
43. Morrison DC, Silverstein R, Luchi M, Shnyra A. Structure-function relationships of bacterial endotoxins. Contribution to microbial sepsis. Infect. Dis. Clin. North Am. 1999;13:313-340.
44. Degryse E, Dietrich M, Nguyen M, Achstetter T, Charlier M, Charpigny G, Gaye P, Martal J. Addition of a dipeptide spacer significantly improves secretion of ovine trophoblast interferon in yeast. Gene 1992;118:47-53.
45. Charlier M, Hue D, Boisnard M, Martal J, Gaye P. Cloning and structural analysis of two distinct families of ovine interferon-α genes encoding functional class II and trophoblast (oTP) α-interferon. Mol. Cell. Endocrinol. 1991;76:161-171.
46. L'Haridon RM, Huynh L, Assal NE, Martal J. A single intrauterine infusion of sustained recombinant ovine interferon-tau extends corpus luteum lifespan in cyclic ewes. Theriogenology 1995; 43:1031-1045.
47. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S, Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C, Rozenbaum W, Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.
48. Soos JM, Mujtaba MG, Subramaniam PS, Streit WJ, Johnson HM. Oral feeding of interferon tau can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. J. Neuroimmunol. 1997;75:43-50.
49. Hempel G, Galle PR, Lohr HF. Quantitative analysis of specific Th1/Th2 helper cell responses and IgG subtype antibodies in interferon-alpha-treated patients with chronic hepatitis C. J. Med. Virol. 2001;64:340-349.
50. Del Prete GF, De Carli M, Mastromauro C, Biagiotti R, Macchia D, Falagiani P, Ricci M, Romagnani S. Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production. J. Clin. Invest. 1991;88:346-350.
51. Knolle PA, Uhrig A, Protzer U, Trippler M, Duchmann R, Meyer ZM, Buschenfelde KH, Gerken G. Interleukin-10 expression is autoregulated at the transcriptional level in human and murine Kupffer cells. Hepatology 1998;27:93-99.
52. Barcellini W, Rizzardi GP, Borghi MO, Fain C, Lazzarin A, Meroni PL. Th1 and Th2 cytokine production by peripheral blood mononuclear cells from HIV-infected patients. AIDS 1994;8:757-762.
53. Galanaud P, Fior R, Boue F, Emilie D. Immunointervention based on Th2-type cytokines in HIV infection. Eur. Cytokine Netw. 1997;8:315-316.
54. Jansson A, Ernerudh J, Kvarnstrom M, Ekerfelt C, Vrethem M. Elispot assay detection of cytokine secretion in multiple sclerosis patients treated with interferon-beta 1 a or glatiramer acetate compared with untreated patients. Mult. Scler. 2003;9:440-445.
55. Olek MJ, Smith DR, Cook SL, Khoury SJ, Weiner HL. Phase I study of oral recombinant ovine interferon-tau in relapsing-remitting multiple sclerosis. Neurology 2001;56(Suppl. 3):A76.